Review top news and interview highlights from the week ending November 11, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.
The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.
The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.
Recent communication with the FDA suggests that the agency's decision might be delayed past Q1 2023.